Steve Andrzejewski is a pharmaceutical industry leader who consistently generates results, beyond expectations, across multiple therapeutic areas for Rx, consumer and generic products. Examples include taking Claritin from its original goal of peak annual sales of $150 million to $3 billion by realigning the strategic direction to engage the consumer market; and doubling expected growth at King Pharmaceuticals between ’05 and ’07 to reach $2.14 billion in revenues. 

Andrzejewski has had extensive success in BD, P & L management, R&D, shareholder relations, fundraising and direct manufacturing, and is a Board member of start-up and forward looking enterprises. Andrzejewski delivers significant growth in revenues and profits in challenging and changing environments. Additionally, Andrzejewski manages R&D strategically and efficiently, placing necessary resources to the best opportunities. He is an innovator who creates industry “best practices'' resulting in the multi-billion dollar Claritin/Clarinex product line, and his creative thinking led to a new patent being issued for Spiritus Pharmaceuticals. Andrzejewski is a turnaround specialist that led to King Pharmaceuticals being sold to Pfizer and Nycomed USA being sold to Sandoz.